Beijing Luzhu Biotechnology Co (HKSE:02480) Debt-to-Equity : 0.02 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Debt-to-Equity?

Beijing Luzhu Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$10.94 Mil. Beijing Luzhu Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$12.63 Mil. Beijing Luzhu Biotechnology Co's Total Stockholders Equity for the quarter that ended in Jun. 2023 was HK$1,259.79 Mil. Beijing Luzhu Biotechnology Co's debt to equity for the quarter that ended in Jun. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's Debt-to-Equity or its related term are showing as below:

HKSE:02480' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02 Med: 0.01 Max: 0.02
Current: 0.02

During the past 3 years, the highest Debt-to-Equity Ratio of Beijing Luzhu Biotechnology Co was 0.02. The lowest was -0.02. And the median was 0.01.

HKSE:02480's Debt-to-Equity is ranked better than
88.08% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:02480: 0.02

Beijing Luzhu Biotechnology Co Debt-to-Equity Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Debt-to-Equity Chart

Beijing Luzhu Biotechnology Co Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-0.02

0.01

0.02

Beijing Luzhu Biotechnology Co Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	-0.02	N/A	0.01	0.02	0.02

Competitive Comparison of Beijing Luzhu Biotechnology Co's Debt-to-Equity

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Luzhu Biotechnology Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's Debt-to-Equity falls into.

Beijing Luzhu Biotechnology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Beijing Luzhu Biotechnology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	12.528)	/	1046.882
	=	0.01

Beijing Luzhu Biotechnology Co's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.938	+	12.634)	/	1259.787
	=	0.02

Beijing Luzhu Biotechnology Co (HKSE:02480) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Beijing Luzhu Biotechnology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN

Website

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines